The London-based biotechnology firm raised the capital from backers including Cantos Ventures and Y Combinator.
"The global pandemic has catapulted RNA therapeutics into the mainstream, yet the field is constrained to targeting the liver. Sixfold’s iterative platform technology and use of machine learning will unlock the power of mRNA and RNAi for many diseases across various tissue types. We are delighted to support the Company in this seed round and look forward to their rapid progress over the coming years."
The seed round was led by Metaplanet Holdings with backing from several institutional investors and angels.
"We are thrilled to have closed our first external investment round, which was so popular we could have filled 2 or 3 times over. We are excited to kick on and start building out our fleet at scale, starting with our 11 satellite constellation for night time imagery"
Notion Capital led the seed investment, which will accelerate product development.
"We believe the Easol team has developed an incredible solution which has become the go-to platform for the world’s best experience creators who are passionate about the experience they deliver every day and not just selling things. Ben’s and Lisa’s deep domain expertise has already translated into rapid commercial growth with high demand that this round will support with more resources in product, marketing, sales and increasing the company’s global footprint. It’s rare for a company at their stage to have such strong signs of product-market fit. In fact, their SaaS metrics are some of the best we’ve ever seen."
